February 5, 2010 — Results from 8 clinical trials show that recombinant human thrombin (rThrombin; Recothrom, ZymoGenetics, Inc) is well tolerated in several surgical settings for topical hemostasis ...

The leading cause of death due to injuries in war is excessive bleeding. A KAIST research team, in which an Army Major participated, has tackled this issue head-on. By developing a next-generation ...

Routine use of expensive hemostatic agents during RALPN does not seem to be justified. The use of hemostatic agents (HAs) during standard robotic-assisted laparoscopic partial nephrectomy (RALPN) does ...

United Health Products, Inc. (OTCQB: UEEC) today provided a status update on its discussions with the Food & Drug ...

Uncontrolled bleeding during surgery remains one of the deadliest medical emergencies. Injuries to internal organs such as the liver or spleen are especially dangerous because bleeding is difficult to ...

Market valued at $1.45B in 2024 grows at 10.4% CAGR driven by biocompatible hemostatic solutions in surgical and trauma care settings. The shift toward nature-derived hemostatic solutions reflects ...